UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 TOMI ENVIRONMENTAL SOLUTIONS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Florida 59-1947988 (I.R.S. Employer Identification No.) 8430 Spires Way Frederick, Maryland 21701 (Address of principal executive offices) (Zip Co ...

TOMI Environmental Solutions, Inc. (NASDAQ:TOMZ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants John Nesbett - Investor Relations Halden Shane - Chief Executive Officer and Chairman E.J. Shane - Chief Operating Officer Nick Jennings - Chief Financial Officer Conference Call Participants John Nelson - Private Investor Operator Greetings. Welcome to the TOMI Environmental Solutions, Inc. Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please no ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 000-09908 TOMI ENVIRONMENTAL SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Florida 59-1947 ...

TOMI Environmental Solutions, Inc. (NASDAQ:TOMZ) Q2 2023 Earnings Call Transcript August 11, 2023 4:30 PM ET Company Participants John Nesbett - IMS IR Dr. Halden Shane - CEO and Chairman E.J. Shane - COO Nick Jennings - CFO Conference Call Participants Todd Felte - AGES Financial Services John Nelson - Private Investor Operator Greetings. Welcome to the TOMI Environmental Solutions Incorporated Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. ...

Financial Performance - Net sales for the three months ended June 30, 2023, increased to $2.77 million, a 90.2% increase compared to $1.46 million for the same period in 2022[21]. - Gross profit for the six months ended June 30, 2023, was $2.64 million, up 12.8% from $2.34 million in the same period of 2022[21]. - The net loss for the three months ended June 30, 2023, was $88,591, a significant improvement compared to a net loss of $862,382 for the same period in 2022[21]. - For the six months ended June 30, 2023, the net loss was $1,276,078, an improvement from a net loss of $1,521,865 in the same period of 2022, representing a decrease of approximately 16%[29]. - Revenue for Q2 2023 was $2,775,000, representing a 90% increase or $1,300,000 compared to Q2 2022[126]. - Revenue for the first half of 2023 was $4,357,000, reflecting a 16% growth over the same period in the prior year[127]. - Loss from operations improved by 90% for Q2 2023 compared to the same period last year[128]. Assets and Liabilities - Total assets decreased to $13.35 million as of June 30, 2023, down from $15.50 million at the end of 2022, representing a decline of approximately 13.8%[15]. - Shareholders' equity decreased to $10.38 million as of June 30, 2023, down from $11.45 million at the end of 2022, reflecting a decline of approximately 9.3%[19]. - Cash and cash equivalents decreased to $1.57 million as of June 30, 2023, from $3.87 million at the end of 2022, a decline of about 59.3%[15]. - Total current liabilities decreased to $2.26 million as of June 30, 2023, down from $3.29 million at the end of 2022, a reduction of approximately 31.2%[17]. - Total inventories as of June 30, 2023, were $4,412,786, a slight decrease from $4,495,999 as of December 31, 2022[83]. - Property and equipment, net as of June 30, 2023, was $1,238,241, down from $1,335,331 as of December 31, 2022[85]. Revenue Breakdown - Total revenue for the three months ended June 30, 2023, was $2,775,000, a 90.4% increase from $1,458,000 in the same period of 2022[65]. - SteraMist product revenue for the three months ended June 30, 2023, was $2,272,000, compared to $1,134,000 in 2022, reflecting a 100.9% increase[65]. - Service and training revenue for the three months ended June 30, 2023, was $503,000, up from $324,000 in 2022, representing a 55.4% increase[65]. - Revenue from the United States for the three months ended June 30, 2023, was $2,602,000, compared to $1,206,000 in 2022, marking a 116.5% increase[66]. Expenses - Total operating expenses for the three months ended June 30, 2023, were $1.79 million, slightly up from $1.78 million in the same period of 2022[21]. - Research and development expenses for the three months ended June 30, 2023, were approximately $74,000, down from $99,000 in 2022, a decrease of 25.3%[79]. - Advertising and promotional expenses for the three months ended June 30, 2023, were approximately $142,000, a decrease from $158,000 in 2022, reflecting a 10.1% reduction[78]. - The company reported a depreciation and amortization expense of $179,336 for the six months ended June 30, 2023, compared to $165,043 for the same period in 2022, reflecting an increase of approximately 9%[29]. Cash Flow - Cash flow from operating activities resulted in a net cash used of $2,198,350 for the six months ended June 30, 2023, compared to $450,954 for the same period in 2022, indicating a significant increase in cash outflow[29]. - The ending cash and cash equivalents as of June 30, 2023, were $1,574,088, down from $4,800,408 at the end of June 30, 2022, reflecting a decrease of approximately 67%[31]. - Net cash used in operations for the first half of 2023 was approximately $2,198,000[200]. Market and Product Developments - The company launched its fourth generation SteraMist Environment System, which operates at 24 volts and features eight outputs, enhancing its efficiency and usability[150]. - The SteraMist BIT solution product line now includes five options, ranging from a 32-ounce bottle to a 55-gallon drum, supporting the company's razor/razor-blade business model[151]. - The company has established partnerships with domestic and international distributors to expand its market reach, including a distributor agreement with Avantor, a Fortune 500 company[140][138]. - The company is focusing on long-term projects and validations in the life sciences sector, with expectations for installations to materially impact results in 2023 and 2024[161]. - The company has maintained relationships with large pharmaceutical companies and has treated four BSL-3 research laboratories recently, indicating growth in its iHP service department[161]. Customer and Sales Insights - Three customers accounted for 57% of net revenue for Q2 2023, highlighting customer concentration risk[120]. - The company has received 15 orders for CES systems since the product launch, indicating strong market demand[134]. - The integration of TOMI's technology into the Cell Shuttle enhances decontamination capabilities, aligning with industry needs[132]. - The total recognized revenue and customer sales backlog for the three months ended June 30, 2023, was approximately $3,261,000, consisting of recognized revenue of $2,775,000 and a customer sales backlog of approximately $486,000[145]. Future Outlook - The company anticipates achieving profitability in Q4 2023, supported by strong second-quarter results[178]. - The company expects new product introductions to positively impact net sales, cost of sales, and operating expenses during the fiscal year[152]. - Recent studies demonstrated SteraMist's effectiveness in reducing microbial contamination in cannabis without affecting potency[195]. - The company is actively pursuing additional EPA registrations to enhance its market presence in the food safety sector[193].

Financial Data and Key Metrics Changes - For Q1 2023, consolidated net revenue was $1,582,000, down from $2,309,000 in Q1 2022, reflecting a decrease of approximately 31.5% [31] - Consolidated gross profit margin was 59.5%, compared to 61.4% in the prior year [31] - Consolidated operating loss increased to $1,188,000 from $660,000 year-over-year [31] - Consolidated net loss was $1,187,000 or $0.06 per share, compared to a net loss of $659,000 or $0.03 per share in the previous year [31] - Adjusted EBITDA was a loss of $941,000 compared to a loss of $280,000 in the prior year [31] Business Line Data and Key Metrics Changes - The recognized revenue for the quarter was $1,582,000, with a customer sales backlog of approximately $1,547,000, totaling around $3,129,000 [5] - Higher margin solution sales are growing, with recurring solution sales currently accounting for about 15% of total revenue, expected to increase as more CES systems are put into production [35][36] Market Data and Key Metrics Changes - The EPA's proposed reduction of ethylene oxide emissions by 80% at 86 commercial sterilization locations in the U.S. presents a significant market opportunity for TOMI's SteraMist products [6] - The company is expanding its distribution network, including partnerships with various medical and scientific suppliers, which is expected to enhance market reach [8][9] Company Strategy and Development Direction - The company is optimistic about improved financial results for the remainder of 2023, driven by an expanding sales backlog and distribution network [6] - TOMI is focusing on international expansion, particularly in Europe and Africa, to establish partnerships and increase sales [18][19] - The company is actively seeking to enhance its presence in the cannabis industry, with ongoing studies demonstrating the efficacy of SteraMist in eliminating contaminants [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability in the second half of 2023, despite the lumpy nature of revenue recognition [37] - The company is working on multiple fronts to strengthen its market position, including expanding its product offerings and enhancing customer engagement [30] - Management highlighted the importance of ongoing studies and partnerships in driving future growth and revenue [13][19] Other Important Information - The company has launched a new website to improve customer engagement and reflect its mission [16] - TOMI is involved in various studies to prove the efficacy of its products against specific pathogens, which could lead to new market opportunities [13][16] Q&A Session Summary Question: What is the recurring revenue from the BIT solution? - Management indicated that margins on recurring solution sales are higher than typical, around 60%, with 15% of revenue attributed to these sales [34][35] Question: Will the company achieve profitability in 2023? - Management reaffirmed the goal of profitability in the second half of the year, citing strong expectations for improved performance [37] Question: How does the custom engineered systems business drive predictable sales? - Management explained that upfront equipment purchases lead to consistent solution usage, enhancing predictability in revenue [39] Question: Any updates on competition from LifeClean? - Management stated that there is no comparison between SteraMist and LifeClean's product, emphasizing SteraMist's superior efficacy and environmental safety [41][42] Question: What is the status of the shield study? - Management noted that the study is with the authors, and results are expected to be discussed in the next quarter [43] Question: Any progress with the large seed company? - Management confirmed positive progress in food safety testing and ongoing discussions with potential users [44] Question: Is the company comfortable with its current cash position? - Management expressed comfort with the cash position but emphasized the need for deposits from CES systems to improve cash flow [47]

Financial Performance - Net sales for Q1 2023 were $1.58 million, a decrease of 31.5% compared to $2.31 million in Q1 2022[18]. - Gross profit for Q1 2023 was $941,237, down 33.7% from $1.42 million in the same period last year[18]. - The net loss for Q1 2023 was $1.19 million, compared to a net loss of $659,484 in Q1 2022, indicating a 80.5% increase in losses year-over-year[21]. - Total revenue for Q1 2023 was $1,582,000, a decrease of $727,000 or 31% compared to Q1 2022 revenue of $2,309,000[196]. - Total operating expenses for Q1 2023 were $2,129,000, an increase of $48,000 from $2,081,000 in Q1 2022[193]. - Net loss for Q1 2023 was $1,187,000, compared to a net loss of $659,000 in Q1 2022, reflecting an increase in loss of $528,000[195]. Assets and Liabilities - Total assets decreased to $13.74 million as of March 31, 2023, down from $15.50 million at the end of 2022, representing a decline of approximately 11.2%[12][16]. - Cash and cash equivalents decreased to $2.47 million at the end of Q1 2023, down from $3.87 million at the end of 2022, a decline of 36.1%[24]. - Total current liabilities decreased to $2.53 million as of March 31, 2023, down from $3.29 million at the end of 2022, a reduction of 23.0%[14][16]. - Total shareholders' equity as of March 31, 2023, was $10,471,000, a decrease from $11,448,000 as of December 31, 2022[191]. Revenue Breakdown - SteraMist product revenue was $1,276,000 for Q1 2023, down from $1,886,000 in Q1 2022, representing a decline of 32.3%[63]. - Service and training revenue decreased to $306,000 in Q1 2023 from $423,000 in Q1 2022, a reduction of 27.7%[63]. - Revenue from the United States was $1,128,000 in Q1 2023, down from $1,879,000 in Q1 2022, reflecting a decline of 40%[63]. - International revenue for Q1 2023 was approximately $454,000, an increase of $24,000 or 6% compared to $430,000 in Q1 2022[201]. Expenses - Research and development expenses increased to $70,520 in Q1 2023, up 90.2% from $37,076 in Q1 2022[18]. - Total accrued expenses and other current liabilities decreased from $728,703 as of December 31, 2022, to $528,800 as of March 31, 2023, reflecting a reduction of approximately 27.4%[109]. - Professional fees decreased by approximately $54,000, or 28%, to $137,000 for the three months ended March 31, 2023, compared to $191,000 in the prior year[205]. - Selling expenses increased by approximately $36,000, or 11%, to $377,000 for the three months ended March 31, 2023, compared to $341,000 in the prior year[208]. Market and Product Development - The company continues to focus on expanding its market presence through its SteraMist® brand, which is actively used for COVID-19 decontamination[25]. - The company launched its fourth generation SteraMist Environment System, which features eight outputs and improved efficiency in hydrogen peroxide conversion[140]. - New product introductions are expected to positively impact net sales, cost of sales, and operating expenses during the fiscal year[142]. - The Food Safety division is poised for significant growth due to emerging challenges in food safety and compliance with new regulations, including the Food Safety Modernization Act[159]. Customer and Sales Information - Two customers accounted for 26% of net revenue for the three months ended March 31, 2023, compared to three customers accounting for 41% in the same period of 2022[115]. - Recognized revenue for the three months ended March 31, 2023, was approximately $1,582,000, with a customer sales backlog of approximately $1,547,000[135]. - The company added one independent manufacturing representative and five distributors in Q1 2023, expanding its sales channels and distribution networks[120]. Legal and Compliance - The company has no legal matters that would materially affect its financial condition or results of operations as of the reporting date[102]. - The provision for income tax for the three months ended March 31, 2023, was $0, with a valuation allowance of $5,664,000 for deferred tax assets not expected to be realized[112].

TOMI Environmental Solutions, Inc. (NASDAQ:TOMZ) Q4 2022 Results Conference Call March 16, 2023 4:30 PM ET Company Participants John Nesbett - IMS IR Dr. Halden Shane - CEO and Chairman E.J. Shane - COO Nick Jennings - CFO Conference Call Participants Sameer Joshi - H.C. Wainwright Operator Good afternoon, and welcome to the TOMI Environmental Fourth Quarter and Year-End 2022 Earnings Conference Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, John Nesbett from IMS In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-09908 TOMI ENVIRONMENTAL SOLUTIONS, INC. (Exact name of registrant as specified in its charter) FLORIDA 59-1947988 (State or other jurisdiction ...

TOMI Environmental Solutions, Inc. (NASDAQ:TOMZ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants John Nesbett - IMS Investor Relations Halden Shane - Chairman and CEO Conference Call Participants Sameer Joshi - H.C. Wainwright Operator Good day, everyone, and welcome to today's TOMI Environmental Solutions, Inc. Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn the conference over to John Nesbett of IMS Investor Rel ...